News for BioMimetic Therapeutics, Inc. - Google Finance

Drug Delivery Partnering Terms and Agreements

Thu, 13 Jun 2013 17:11:58 GMT

Drug Delivery Partnering Terms and Agreements
Sacramento Bee - Jun 13, 2013

Big pharma drug delivery partnering company profiles Abbott Actavis Inc (formerly Watson Pharmaceuticals) Actavis (merged with Watson Pharmaceuticals Oct 2012) Actelion Allergan Amgen Astellas AstraZeneca Baxter International Bayer Biogen Idec ...

BioRegenerative Sciences, Inc. to Present S2RM® Stem Cell Technology at 3rd ...

Thu, 13 Jun 2013 17:23:15 GMT

BioRegenerative Sciences, Inc. to Present S2RM® Stem Cell Technology at 3rd ...
Watch List News (press release) - Jun 13, 2013

Dr. Maguire added, S2RM® is a biomimetic that uses the molecules released from multiple stem cell types in a patent pending process to develop therapeutics and medical procedures that mimic mother nature's healing processes. When the body is diseased ...

NanoViricides Submits DengueCide™ Orphan Drug Designation Application to ...

Tue, 11 Jun 2013 07:49:01 GMT

NanoViricides Submits DengueCide™ Orphan Drug Designation Application to ...
DailyFinance - Jun 11, 2013

(BUSINESS WIRE)-- NanoViricides, Inc. (OTC BB: NNVC) (the "Company") announced today that it has filed an Orphan Drug application with the Office of Orphan Product Development (OOPD) of the US FDA for DengueCide™, its drug candidate for the treatment ...

Product Developments, Partnerships and Validated Clinical Trials Help ...

Thu, 06 Jun 2013 12:03:44 GMT

Product Developments, Partnerships and Validated Clinical Trials Help ...
MarketWatch (press release) - Jun 6, 2013

On June 3, 2013, Align Technology Inc. (Align Technology) and Henry Schein Dental, the US dental business of Henry Schein, Inc., jointly announced the introduction of Realine, an entry level, five-stage clear aligner product designed for very minor ...

NanoViricides Submits DengueCide(TM) Orphan Drug Designation Application ...

Mon, 10 Jun 2013 11:06:57 GMT

NanoViricides Submits DengueCide(TM) Orphan Drug Designation Application ...
Wall Street Journal (press release) - Jun 10, 2013

NanoViricides, Inc. (OTC BB: NNVC) (the "Company") announced today that it has filed an Orphan Drug application with the Office of Orphan Product Development (OOPD) of the US FDA for DengueCide(TM), its drug candidate for the treatment of dengue and ...

Wright Medical Stays Neutral

Wed, 22 May 2013 17:51:22 GMT

Wright Medical Stays Neutral
Zacks.com - May 22, 2013

The combination with BioMimetic Therapeutics will improve competitive advantage. However, dilution is expected to contribute to ... In addition, Conceptus, Inc. (CPTS) carries a Zacks Rank #1 (Strong Buy) and warrants a look. tooltip here... Get the ...

Wright Medical Group Inc Completes Acquisition Of BioMimetic Therapeutics, Inc.

Fri, 01 Mar 2013 10:59:00 GMT

Wright Medical Group Inc Completes Acquisition Of BioMimetic Therapeutics, Inc.
Reuters Key Development - Mar 1, 2013

Law Office of Brodsky & Smith, LLC Announces Investigation of BioMimetic Therapeutics Inc

Tue, 20 Nov 2012 19:57:00 GMT

Law Office of Brodsky & Smith, LLC Announces Investigation of BioMimetic Therapeutics Inc
Reuters Key Development - Nov 20, 2012

Faruqi & Faruqi, LLP Announces Investigation Of Board Of Directors Of BioMimetic Therapeutics Inc

Tue, 20 Nov 2012 00:01:00 GMT

Faruqi & Faruqi, LLP Announces Investigation Of Board Of Directors Of BioMimetic Therapeutics Inc
Reuters Key Development - Nov 20, 2012

Rigrodsky & Long, P.A. Announces Investigation Of BioMimetic Therapeutics Inc. Buyout

Mon, 19 Nov 2012 17:23:00 GMT

Rigrodsky & Long, P.A. Announces Investigation Of BioMimetic Therapeutics Inc. Buyout
Reuters Key Development - Nov 19, 2012